Immuneering (IMRX) vs Nautilus Biotechnology (NAUT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Nautilus Biotechnology (NAUT) has outperformed Immuneering (IMRX) over the past year, gaining 126.3% versus a loss of 36.8%. Over five years, NAUT leads with a -65.7% price change compared with -84.5% for IMRX. Immuneering is the larger company by market cap ($249.7 million vs $249.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMRX | NAUT |
|---|---|---|
| Share price | $3.86 | $1.96 |
| Market cap | $249.73M | $249.42M |
| 1-day change | +0.78% | +10.73% |
| YTD return | -41.34% | +0.51% |
| 1-year return | -36.82% | +126.33% |
| 5-year return | -84.47% | -65.67% |
| EPS (TTM) | $-0.93 | $-0.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.48 | $4.31 |
| 52-week low | $3.74 | $0.82 |
| Distance from 52-week high | -54.48% | -54.52% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +344.82% | +95.41% |
| Average volume | 694.54K | 2.59M |
| Shares outstanding | 64.70M | 127.26M |
| Employees | 57 | 127 |
| Sector | Health Care | Industrials |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NAUT has outperformed IMRX by 163.2 percentage points over the past year.
- The two companies sit in different sectors: Immuneering in Health Care and Nautilus Biotechnology in Industrials.
About Immuneering
IMRX stock →Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
About Nautilus Biotechnology
NAUT stock →Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis.
Industrials · Biotechnology: Laboratory Analytical Instruments · 127 employees
IMRX vs NAUT FAQ
Which is bigger, Immuneering or Nautilus Biotechnology?
Immuneering (IMRX) is larger, with a market capitalization of $249.73M compared with $249.42M for Nautilus Biotechnology (NAUT).
Which stock has performed better over the past year, IMRX or NAUT?
NAUT returned +126.33% over the past 12 months, compared with -36.82% for IMRX (price return, excluding dividends). Past performance does not predict future results.
Are Immuneering and Nautilus Biotechnology in the same industry?
No. Immuneering is in the Health Care sector, while Nautilus Biotechnology is in Industrials.